Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Rx smoking cessation pill

This article was originally published in The Tan Sheet

Executive Summary

FDA has approved Pfizer's smoking cessation drug Chantix (varenicline) for prescription use, the agency announces May 11. The drug, which Pfizer originally had intended to market as Champix, is the first nicotine agonist approved by FDA, and the first new Rx medication approved for smoking cessation in more than a decade, according to the firm. Varenicline works by binding to nicotine receptors in the brain, thereby "providing some nicotine effects to ease withdrawal symptoms and...blocking the effects of nicotine from cigarettes if [people] resume smoking," FDA states. Pfizer expects Chantix to launch in the second half of 2006. The firm has stated in the past that it will draw from its Nicorette experience when developing DTC ads for Chantix (1"The Tan Sheet" Feb. 9, 2004, p. 5)...

Related Content





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts